2. Summary table of included studies.
| Review Manager ID | Study design | Agent | Route |
Child. (< 12 yrs) |
Adolesc. (12‐17 yrs) |
Mean age | No | % Female |
| Paracetamol | ||||||||
| Hämäläinen 1997a | Cross‐over | — | PO | Yes | Yes | 10.7 | 80 | 50% |
| Ibuprofen | ||||||||
| Hämäläinen 1997a | Cross‐over | — | PO | Yes | Yes | 10.7 | 78 | 50% |
| Lewis 2002 | Parallel | — | PO | Yes | No | 9.0 | 84 | ND |
| Evers 2006 | Cross‐over | — | PO | Yes | Yes | 13.9 | 29 | 56% |
| Triptans (< 12 years) | ||||||||
| Ho 2012 | Parallel | Rizatriptan | PO | Yes | NA | ND | 200 | 44% |
| Ueberall 1999 | Cross‐over | Sumatriptan | IN | Yes | No | 8.2 | 14 | 50% |
| Hämäläinen 2002 | Cross‐over | Sumatriptan | IN | Yes | No | 9.7 | 59 | 54% |
| Triptans (12‐17 years) | ||||||||
| Linder 2008 | Parallel | Almotriptan | PO | No | Yes | 14.4 | 714 | 60% |
| Winner 2007 | Parallel | Eletriptan | PO | No | Yes | 14.0 | 274 | 57% |
| Rothner 1997 | Parallel | Naratriptan | PO | No | Yes | 14.3 | 300 | 54% |
| Ho 2012 | Parallel | Rizatriptan | PO | NA | Yes | ND | 570 | 61% |
| Visser 2004a | Parallel | Rizatriptan | PO | No | Yes | 14.2 | 476 | 55% |
| Winner 2002 | Parallel | Rizatriptan | PO | No | Yes | 14.0 | 296 | 54% |
| Ahonen 2006 | Cross‐over | Rizatriptan | PO | Yes | Yes | 12.0 | 116 | 54% |
| Callenbach 2007 | Cross‐over | Sumatriptan | IN | No | Yes | 13.6 | 46 | 78% |
| Rothner 1999b | Parallel | Sumatriptan | PO | No | Yes | 13.6 | 92 | 52% |
| Winner 2000 | Parallel | Sumatriptan | IN | No | Yes | 14.1 | 507 | 52% |
| Hämäläinen 1997b | Cross‐over | Sumatriptan | PO | Yes | Yes | 12.3 | 23 | 52% |
| Rothner 1999c | Parallel | Sumatriptan | PO | No | Yes | 13.5 | 102 | 42% |
| Fujita 2014 | Parallel | Sumatriptan | PO | Yes | Yes | 14.1 | 144 | 58% |
| Winner 1997 | Cross‐over | Sumatriptan | PO | No | Yes | 13.9 | 298 | 58% |
| Winner 2006 | Parallel | Sumatriptan | IN | No | Yes | 14.3 | 731 | 55% |
| Ahonen 2004 | Cross‐over | Sumatriptan | IN | Yes | Yes | 12.4 | 94 | 46% |
| Rothner 1999a | Parallel | Sumatriptan | PO | No | Yes | 14.1 | 273 | 57% |
| Derosier 2012 | Parallel | Sumatriptan and Naproxen Sodium |
PO | No | Yes | 14.7 | 490 | 59% |
| Lewis 2007 | Cross‐over | Zolmitriptan | IN | No | Yes | 14.2 | 171 | 57% |
| Evers 2006 | Cross‐over | Zolmitriptan | PO | Yes | Yes | 13.9 | 29 | 56% |
| Rothner 2006 | Parallel | Zolmitriptan | PO | No | Yes | 14.2 | 696 | 59% |
| NCT01211145 | Parallel | Zolmitriptan | IN | No | Yes | 14 | 584 | ND |
| Dihydroergotamine | ||||||||
| Hämäläinen 1997c | Cross‐over | — | PO | Yes | Yes | 10.3 | 13 | 38% |
IN: intranasal; NA: not applicable; ND: no data available; No: total number in efficacy analysis (intention‐to‐treat when available); PO: per os (by mouth).